Jump to navigation Jump to search
|Drug class||Nonsteroidal estrogen|
|Chemical and physical data|
|Molar mass||348.486 g·mol−1|
|3D model (JSmol)|
SC-4289 is a synthetic nonsteroidal estrogen which, along with mytatrienediol (SC-6924; Manvene, Anvene), was developed in the late 1950s as a potential treatment for atherosclerosis in men but was never marketed.
- Berichte über die gesamte Physiologie und experimentelle Pharmakologie. Springer-Verlag. p. 332,378.
- Robinson, R. W., Cohen, W. D., & Higano, N. (1956, January). Serum lipid and estrogenic effects of two new „weak estrogens“ in male patients with coronary atherosclerosis. In Circulation (Vol. 14, No. 3, pp. 489-490). 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106: LIPPINCOTT WILLIAMS & WILKINS. http://circ.ahajournals.org/content/circulationaha/14/3/local/back-matter.pdf
- DAVIS FW, SCARBOROUGH WR, MASON RE, SINGEWALD ML, BAKER BM (1958). "Experimental hormonal therapy of atherosclerosis: preliminary observations on the effects of two new compounds". Am. J. Med. Sci. 235 (1): 50–9. PMID 13487586.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|